Formation Bio outlined its AI‑native hub‑and‑spoke model to accelerate clinical development, telling investors and partners the platform can cut cost and time across trial design, execution and regulation. The company has raised large capital infusions to fund its platform-driven approach. Separately, Latent Labs — founded by former DeepMind talent — is positioning AI models to design drug‑like biologics in one step, targeting hard-to-drug proteins. Both companies illustrate the sector’s shift from discovery proofs toward platform-driven translational and clinical execution, with near‑term metrics focused on deal flow, asset throughput and regulatory validation.